Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPR) saw a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 2,080,000 shares, a decrease of 16.8% from the February 13th total of 2,500,000 shares. Approximately 17.5% of the company’s stock are short sold. Based on an average daily volume of 522,500 shares, the days-to-cover ratio is currently 4.0 days.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on JSPR shares. UBS Group assumed coverage on Jasper Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $38.00 price target on the stock. Royal Bank of Canada dropped their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research report on Monday, January 6th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $62.50.

Jasper Therapeutics Stock Down 0.6 %

Shares of NASDAQ:JSPR traded down $0.03 during trading on Wednesday, hitting $5.19. The stock had a trading volume of 222,188 shares, compared to its average volume of 267,512. Jasper Therapeutics has a 12-month low of $4.55 and a 12-month high of $31.01. The stock has a market capitalization of $77.96 million, a price-to-earnings ratio of -1.09 and a beta of 2.23. The stock has a 50-day simple moving average of $5.86 and a two-hundred day simple moving average of $15.49.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). As a group, sell-side analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors have recently added to or reduced their stakes in JSPR. BNP Paribas Financial Markets raised its position in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares during the period. MetLife Investment Management LLC raised its position in Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares during the period. Wells Fargo & Company MN raised its position in Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Jasper Therapeutics in the fourth quarter valued at $223,000. Finally, Tema Etfs LLC acquired a new stake in shares of Jasper Therapeutics in the fourth quarter valued at $266,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.